for media  relypsa inc committed to providing the media with timely and accurate informationthis section offers the following resources for media professionals press releases media fact sheets our perspectives digital library if you are a member of media and have an inquiry please contact us at mediarelypsacom  newsroom for media for investors press releases media fact sheets digital library who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc careers  relypsa inc careersrelypsa is committed to excellence and innovation in every aspect of its science and business within an exciting collaborative research and development environment we offer competitive compensation and benefits we are seeking worldclass professionals who are looking for great opportunities and career growth while providing exceptional contributions to the organization relypsa is an equal opportunity employer job opportunities attention recruiters employment is managed through the human resources department and all candidates are presented through this avenue  contacting our hiring managers directly is not appropriate  complying with this request will be a factor in determining any professional relationship with relypsa to protect the interest of all parties involved relypsa requires a signed agreement to be in place prior to submitting candidate resumes for consideration  relypsa does not accept unsolicited resumes from any source other than directly from candidates for either current or future positions  submission of unsolicited resumes in advance of a signed agreement between relypsa and the recruiter does not create any implied obligation on the part of relypsa if you are interested in developing a recruiting relationship with us you must work directly with human resources  for more details please email recruitingrelypsacom join us our culture careers who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc relypsa inc gut check the evolution ofpolymer science   learn more hyperkalemia from the inside out   learn more introducing veltassa®   learn more important safety information our mission to improve patients’ lives through the discovery development and delivery of therapeutics that leverage polymer science and other novel approaches veltassa® patiromer for oral suspension first commercialized medicine resulting from relypsa’s polymer technology platform important safety information vifor pharma as of september   relypsa became a vifor pharma company  learn more about vifor pharma who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc about us  relypsa inc developing new polymerbased medicines for undertreated conditionsrelypsa is a biopharmaceutical company leading the discovery development and commercialization of polymerbased medicines to treat conditions that are often overlooked and undertreated but that can have a serious impact on patient lives or even be lifethreatening we are focused on developing medicines that will change treatment paradigms relypsa was founded in october  and is headquartered in redwood city calif in september  relypsa became a vifor pharma company learn more about vifor pharma here today we have more than  employees united by a passion for improving people’s lives our unique technology platform includes a proprietary highthroughput chemistry process enabling us to efficiently explore thousands of potential polymer medicines for each disease we seek to address our polymers are nonabsorbed meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body our polymer technology may be able to address many health conditions in need of viable treatment options who we are about us our history mission  values leadership management scientific advisory board giving back charitable contributions  sponsorships medical education investigator sponsored trials about vifor pharma who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc relypsa inc gut check the evolution ofpolymer science   learn more hyperkalemia from the inside out   learn more introducing veltassa®   learn more important safety information our mission to improve patients’ lives through the discovery development and delivery of therapeutics that leverage polymer science and other novel approaches veltassa® patiromer for oral suspension first commercialized medicine resulting from relypsa’s polymer technology platform important safety information vifor pharma as of september   relypsa became a vifor pharma company  learn more about vifor pharma who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc  cardinal way redwood city ca  relypsa inc relypsa inccorporate headquarters  cardinal way  redwood city ca   inforelypsacom for medical information drug safety adverse event reports andor product quality complaints relypsa  medinforelypsacom drugsafetyrelypsacom veltassa™ patient access program veltassa  media mediarelypsacom careers recruitingrelypsacom contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc veltassa®  relypsa inc first new medicine for the treatment of hyperkalemia in more than  years veltassa patiromer for oral suspension is the first commercialized medicine resulting from relypsa’s polymer technology platform veltassa® indication  limitations of use veltassa is a potassium binder approved for the treatment of hyperkalemia veltassa should not be used as an emergency treatment for lifethreatening hyperkalemia because of its delayed onset of action please see important safety information click here for full prescribing information available in powder form veltassa is mixed with water and taken daily its smooth spherical beads bind to potassium in exchange for calcium primarily in the colon the potassium is then excreted from the body through the normal excretion process  veltassa patient access program relypsa is committed to providing people living with hyperkalemia a comprehensive network of patient support services visit veltassacom for more information adverse event reporting important safety information contraindications veltassa is contraindicated in patients with a history of a hypersensitivity reaction to veltassa or any of its components worsening of gastrointestinal motility avoid use of veltassa in patients with severe constipation bowel obstruction or impaction including abnormal postoperative bowel motility disorders because veltassa may be ineffective and may worsen gastrointestinal conditions patients with a history of bowel obstruction or major gastrointestinal surgery severe gastrointestinal disorders or swallowing disorders were not included in clinical studies hypomagnesemia veltassa binds to magnesium in the colon which can lead to hypomagnesemia  in clinical studies hypomagnesemia was reported as an adverse reaction in  of patients treated with veltassa approximately  of patients in clinical trials developed hypomagnesemia with a serum magnesium value   mgdl monitor serum magnesium consider magnesium supplementation in patients who develop low serum magnesium levels adverse reactions the most common adverse reactions incidence ≥  are constipation hypomagnesemia diarrhea nausea abdominal discomfort and flatulence mild to moderate hypersensitivity reactions were reported in  of patients treated with veltassa and included edema of the lips please see full prescribing information by clicking here our medicine veltassa® adverse event reporting what is hyperkalemia who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc relypsa inc names of competitors  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  competition company profile information for sales preparation marketing contacts competition revenue  financial available products company report pharmaceutical manufacturing industry report competitive reports relypsa inc competition relypsa knows that too much of a good thing can be bad for your health a pharmaceutical company relypsa has developed a drug to treat hyperkalemia a potentially lifethreatening condition defined by high levels of potassium in the blood caused by kidney dysfunction the companys first commercialized medicine veltassa patiromer is an orally administered nonabsorbed drug that binds to ingested potassium and reduces its absorption by the body relypsa received fda approval for veltassa in  the company went public in  swiss firm galenica acquired relypsa for  billion in mid top competitors for relypsa inc get a clear understanding of a company’s competitive landscape view competitive landscape report competitors sanofi us services inc top industries for relypsa inc need to access more competitors no problem conduct competitive analysis inform corporate strategy and identify trends get access to over  parameters including sales employees market cap and more call   to talk to a business information consultant request your free trial   top industriesidentify new market opportunities and new strategies for existing markets view industry report industries pharmaceutical manufacturing  industries on file year founded  annual revenue mil  free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days management management scott garland president scott joined relypsa in october  with more than  years of biotechnologypharmaceutical industry experience before becoming president in  scott served as relypsa’s chief commercial officer he has extensive expertise in launching products and building commercial infrastructure to support specialty drugs including within the nephrology community prior to joining relypsa scott was executive vice president and chief commercial officer of exelixis where he led global commercial operations and was responsible for building and leading sales marketing market access and commercial operations before exelixis scott had a nineyear tenure at genentech most recently as vice president avastin franchise where he led a team of more than  people with revenue of  billion while at genentech he held other seniorlevel positions overseeing sales and marketing for a number of products earlier in his career scott held various sales and marketing positions at amgen including overseeing market development for the launch of aranesp® for chronic kidney disease patients scott has a bs in biological sciences from california polytechnic state university san luis obispo and an mba from duke university’s fuqua school of business stephen d harrison senior vice president and chief scientific officer stephen joined relypsa in december  with  years’ tenure in biotechnology and pharmaceutical discovery and development a biochemist and molecular biologist he is highly published and has extensive experience leading productdriven research organizations at all stages from target identification to early clinical development prior to joining relypsa stephen was vice president research biology at nektar therapeutics a leader in polymer conjugate therapeutics where for four years he managed global oncology and pain research efforts prior to nektar he was senior vice president research at kai pharmaceuticals a company focused on peptide modulators of protein interactions while at kai stephen generated one development candidate per year and led discovery efforts including the companys lead compound for the treatment of secondary hyperparathyroidism which served as the basis for the companys eventual acquisition by amgen earlier in his career stephen held senior research positions at chiron corporation and thios pharmaceuticals he holds a phd in molecular biology a ma and ba in biochemistry all from university of cambridge england patrick treanor senior vice president and chief commercial officer patrick joined relypsa in may  as vice president of sales where he assisted with the successful launch of relypsa’s first commercial product he has more than  years of experience in the pharmaceutical industry in sales marketing managed markets and training and development and over  years of senior leadership experience prior to relypsa patrick served as vice president of sales and managed markets at insulet corporation a medical device company before insulet he served as vice president of us sales at amag pharmaceuticals where he assisted in the buildout of its first commercial team and successful launch of its first brand earlier in his career patrick held positions of increasing responsibility at johnson and johnson abbott laboratories and oscient pharmaceuticals including roles as district sales manager brand manager director of sales training and national sales director patrick earned a bs in management from bryant university and an mba from rensselaer polytechnic institute estela alvarez vice president of quality and analytical development estela joined relypsa in september  with more than  years of experience in quality and analytical development in the biotechnologypharmaceutical industry prior to relypsa she was a senior qc specialist at genentech before that she was executive director of qc and analytical development at affymax earlier in her career estela worked at vaxgen as a qc director where she built a team and a gmp laboratory that supported the manufacture of vaccines prior to vaxgen she worked at sugen and scios she began her career at sterling winthrop currently sanofiaventis estela has a bs from the iberoamerican university in mexico city an ms from american university in washington dc and a phd in organic chemistry from the university of maryland ann kich vice president of technical operations ann joined relypsa in february  with more than  years of experience in the pharmaceutical industry prior to relypsa ann founded and was a managing partner at rondaxe enterprises a consulting service that provides global strategic and tactical guidance on cmc aspects of drug development to emerging biotech established pharma and pharma fine chemical supplier companies during the  years she was with rondaxe enterprises she grew the company to include clients in europe the us and asia earlier in her career she was executive director of technical operations for bristolmyers squibb where she had global responsibility for manufacturing network strategy and support at bms she was involved in launching  new drugs into global markets and participated in in and outlicensing evaluations from a manufacturing perspective ann has a bs in chemical engineering from the university of maine orono zane rogers vice president of regulatory affairs zane began consulting for relypsa in january  became a fulltime employee in december  and has led regulatory affairs since june  he has broad experience leading teams and engaging with the fda in research and development planning and execution including all phases of clinical trials advisory committees and nda filings he has extensive experience in commercial regulatory compliance for marketed products prior to joining relypsa zane led a regulatory consulting practice whose clients included intermune exelixis acelrx neos therapeutics and newlink genetics he has worked in numerous therapeutic areas including nephrology pulmonology oncology dermatology and pain prior to consulting zane held roles of increasing responsibility at affymax he began his career at connectics corporation now a glaxosmithkline company zane has a ba from purdue university and an ma in ethics from virginia tech he holds the us rac certification from the regulatory affairs professionals society zane has served on various biotechnology industry association bio working groups and on geron’s embryonic stem cell research oversight committee alain romero vice president of medical and scientific affairs alain joined relypsa in august  with  years of experience in clinical research and development medical affairs and business development he has led clinical programs across a wide range of therapeutic areas including drug delivery antiinfectives neuroscience cardiovascular and respiratory medicine resulting in the successful filing and launch of several new pharmacological treatments before joining relypsa alain was vice president of medical affairs at actelion where he launched opsumit® for pulmonary arterial hypertension previously alain spent  years at pfizer where he worked in early clinical research on licensing assets to latestage development domestically and internationally before becoming responsible for medical affairs prior to joining the biotechnologypharma industry alain practiced at the rennes university hospital was a research fellow at cibageigy and served as a consultant for several companies and on fdamandated audits he was an adjunct professor of medicine at the university of rennes and the miller medical school in miami alain has a pharmd from the university of rennes school of medicine and pharmacy and a phd in biomedical and pharmaceutical sciences from the university of rhode island james shahbazian vice president of finance james joined relypsa in march  and has had increasing responsibility during his tenure with the company he has more than  years of experience in the biotechnologypharmaceutical industry in the areas of corporate finance financial planning and analysis accounting operations and collaborations prior to joining relypsa james served as director financial planning and analysis at exelixis before that he held management roles at titan pharmaceuticals and affymax he received a bs in business administration from the university of san francisco and an mba with a concentration in finance from golden gate university deborah sim vice president and general counsel deborah joined relypsa in september  and now serves as vice president and general counsel prior to relypsa deborah was vice president of legal services at exelixis where she helped the company prepare for the us approval and commercial launch of cometriq® for the treatment of progressive metastatic medullary thyroid cancer during her  years at exelixis she built the company’s legal transactions team and worked on a variety of transactions to support the research development partnering and commercialization of drug products she also initiated the company’s healthcare compliance program before exelixis deborah served as inhouse counsel at peninsula pharmaceuticals earlier in her career she was an associate in the life sciences transactions practice group at cooley llp deborah received a bs in biological sciences from the university of california davis and a jd from santa clara university law school albert liao director of us communications albert joined relypsa in february  with more than  years of experience in healthcare communications spanning corporate product and rd communications most recently he was director rd communications at baxalta now part of shire where he oversaw communications for rd including the newly created global innovation center prior to baxalta he was director global external communications at novartis vaccines where he led public relations for the global launch of bexsero® the first vaccine available to prevent meningococcal serogroup b albert started his career in europe working for the international federation of pharmaceutical manufacturers and associations ifpma and sanofi pasteur msd he received a ba in business economics and international relations from brown university and an mas in international studies from the graduate institute of international studies switzerland who we are about us our history mission  values leadership management scientific advisory board giving back charitable contributions  sponsorships medical education investigator sponsored trials about vifor pharma who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc relypsa inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › relypsa inc print share relypsa inc address relypsa inc  cardinal way redwood city ca contact detailsphone   website wwwrelypsacomcareers wwwrelypsacomcareersjobopportunities drugs associated with relypsa increlypsa inc manufactures markets andor distributes  drug in the united states medications listed here may also be marketed under different names in different countries nonus country and region specific information is not available on this page brandgeneric name average user rating veltassa generic name patiromer class cation exchange resins na latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide relypsa inc  redwood city ca  pharmaceutical  medicinal products redwood city ca pharmaceutical  medicinal products sign in pharmaceutical  medicinal products relypsa inc  cardinal way redwood city ca   san mateo county   select send print   details about relypsa inc in redwood city ca  san mateo county is a business listed in the categories pharmaceutical  medicinal products drugs  drug proprietaries  toiletries pharmaceutical preparation manufacturing drugs and druggists sundries merchant wholesalers pharmaceutical preparations drugs proprietaries  sundries pharmaceutical products manufacture and drugs proprietaries  sundries if you did business with relypsa inc please leave a review and help us improve and help other people also dont forget to mention hubbiz categories pharmaceutical  medicinal products drugs  drug proprietaries  toiletries pharmaceutical preparation manufacturing drugs and druggists sundries merchant wholesalers pharmaceutical preparations drugs proprietaries  sundries pharmaceutical products manufacture drugs proprietaries  sundries share tweet useful content  discover valuable information we organize and make available for you to find over  million pieces of content shared by over  million local businesses and professionals find advice howtos news deals videos and much more  find more content generating recommendations reviews for relypsa inc leave a write a compliment here signin   send  be the first to write a review   explore more like relypsa inc redwood city ca pharmaceutical  medicinal products redwood city ca drugs  drug proprietaries  toiletries pharmaceutical  medicinal products relypsa inc pharmaceutical  medicinal products  cardinal way redwood city ca nekpar therapeutics drugs  drug proprietaries  toiletries  industrial rd san carlos ca alvine pharmaceuticals inc pharmaceutical companies  shoreway rd ste b san carlos ca biostride inc drugs  drug proprietaries  toiletries  douglas ave redwood city ca relievant medsystems drugs  drug proprietaries  toiletries  middlefield rd ste a redwood city ca amur pharamaceuticals inc pharmaceutical  medicinal products  old county rd san carlos ca free qr code download — or embed — copy code business owner claim this business — or — add your business for your website add the followers counter copy customize copyright   hubbiz®  contact  terms of use  privacy policy  request api access  facebook  twitter  some data from acxiom  i own or represent this business  address is a residence  incorrect information  business doesnt exist  i have more information about this business  phone is a personal number  i want to contact hubbiz relypsa inc  company profile from hoover’s  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  profile company profile information for sales preparation marketing contacts competition revenue  financial available products company report pharmaceutical manufacturing industry report competitive reports relypsa inccompany information  cardinal wayredwood city ca  united states  † httpwwwrelypsacom relypsa inc rankings russell  june  top  competitors sanofi us services inc unlock more access to hoover’s build customized email lists  based on your best customer profile learn more about the companies you want to sell to hoover’s has reports on  million companies and  industries  data points are updated each day get real insight written by real people – exclusive research and reviews by our inhouse editorial staff we can deliver our data to your desktop to excel direct to your crm into your custom app or via mobile request your free trial call   today to get started with a free trial   relypsa inc company profile relypsa knows that too much of a good thing can be bad for your health a pharmaceutical company relypsa has developed a drug to treat hyperkalemia a potentially lifethreatening condition defined by high levels of potassium in the blood caused by kidney dysfunction the companys first commercialized medicine veltassa patiromer is an orally administered nonabsorbed drug that binds to ingested potassium and reduces its absorption by the body relypsa received fda approval for veltassa in  the company went public in  swiss firm galenica acquired relypsa for  billion in mid † some telephone numbers on the hoover’s site may be on a country’s do not call or do not contact list including but not limited to the united kingdom’s ctps or tps registers it is a legal requirement that companies do not make sales or marketing calls to registered numbers these are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls by using the information provided on the hoover’s sites as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local state national or international laws and regulations including any local do not call registers or marketing regulations and agree to defend indemnify and hold harmless dun  bradstreet and each of its affiliates in the event your use violates such laws and regulations additional relypsa inc information sales preparation get relevant industry context to prepare for your next sales call – trends competitors news call prep questions and more marketing campaigns find prospect companies that meet the profile of your best customers to maximize campaign roi strategy  planning identify new market opportunities and new strategies for existing markets credit management  finance determine and track a company’s financial condition related tags redwood city ca united states pharmaceutical manufacturing free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising our culture  relypsa inc working together at relypsarelypsa a vifor pharma company is a bay areabased biopharmaceutical company focused on discovering developing and commercializing polymerbased medicines to treat conditions that have a significant impact on people’s lives and could be addressed with a medicine that acts within the gastrointestinal tract every day our team of scientists is hard at work using our deep understanding of polymer science and our polymerbased technology to develop these medicines today we have more than  employees united by a passion for saving and improving patients’ lives at relypsa we put patients first we make decisions based on patients’ wellbeing and partner with medical foundations to support their near and longterm patient initiatives we are committed to providing patients in need access to our medicines in turn we take care of ourselves our leadership team is committed to ensuring that our place of work is supportive collaborative friendly and – most importantly – fun we come together over company lunches we ride a mechanical bull in the parking lot and we jog together on the waterfront we also raise funds and walk as a team at events that support our mission of improving patients’ lives   join us our culture careers who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions who we are about us our history mission  values leadership giving back about vifor pharma what we do our innovative polymer science our perspective our medicine veltassa® adverse event reporting what is hyperkalemia join us our culture careers newsroom for media for investors press releases media fact sheets digital library contact us directions   relypsa inc   all rights reserved privacy policy terms of use website design hane chow inc flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft relypsa inc  patrick henry dr santa clara ca pharmaceutical productswholesale  mapquest relypsa inc  patrick henry dr santa clara ca  reviews   website menu  reservations make reservations order online tickets tickets see availability nearby directions  sponsored topics see a problem let us know legal help flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     relypsa announces european approval of veltassa® to treat adult patients with hyperkalemia elevated blood potassium levels english français register sign in relypsa announces european approval of veltassa® to treat adult patients with hyperkalemia elevated blood potassium levels july    et  source relypsa inc today’s european commission approval is the second worldwide in the us more than  patients have been treated with veltassa since it was approved by the fda in patients with advanced chronic kidney disease ckd andor heart failure are especially susceptible to hyperkalemia which if untreated can lead to abnormal heart rhythms and even sudden deaththe first launches of veltassa in europe are anticipated by yearend  or early  redwood city calif july   globe newswire  relypsa inc a vifor pharma group company today announced that the european commission ec has approved the marketing authorization application maa for veltassa® patiromer for the treatment of hyperkalemia or elevated blood potassium levels veltassa which is the brand name for patiromer in both the us and europe is approved for marketing in all  eu countries and in iceland liechtenstein and norway vifor pharma group plans to launch veltassa in europe by the end of  or in early  “the european approval of veltassa marks the first regulatory approval for this important medicine outside the us further validating our innovative polymer science” said scott garland president of relypsa “in the us we are encouraged by the growing acceptance and uptake of veltassa by clinicians and patients in the  months since we launched veltassa more than  patients with hyperkalemia a serious and often chronic health concern have been treated with it we look forward to working with our colleagues at vifor pharma group to help bring veltassa to patients in europe where a new daily treatment for hyperkalemia is needed” in the eu veltassa is indicated for the treatment of adults with hyperkalemia and the summary of product characteristics smpc notes that this includes those who develop hyperkalemia while being treated with renin angiotensin aldosterone system raas inhibitor therapy nearly all patients treated with veltassa in the clinical development program were on raas inhibitors at baseline in the united states veltassa was approved by the us food and drug administration for the treatment of hyperkalemia in october  becoming the first new medicine for this condition in more than  years marketing authorization applications for veltassa have been submitted and are under review in switzerland and australia vifor pharma plans to submit applications in other markets worldwide patients with advanced ckd andor heart failure are especially susceptible to hyperkalemia including the  million people in the united states who have stage  or  ckd andor heart failure hyperkalemia can cause abnormal heart rhythms and even sudden death there are often no warning signs meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events some medicines that are often prescribed to people with ckd and heart failure to help delay progression of their underlying disease can cause hyperkalemia as a side effect these include raas inhibitors such as angiotensin receptor blockers arbs aldosterone antagonists aas angiotensinconvertingenzyme ace inhibitors and mineralocorticoid receptor antagonists mra about veltassaveltassa is a sodiumfree potassium binder approved for the treatment of hyperkalemia veltassa should not be used as an emergency treatment for lifethreatening hyperkalemia because of its delayed onset of action made in powder form consisting of smooth spherical beads veltassa is mixed with water onethird of a cup and taken onceaday with food veltassa is not absorbed and acts within the gastrointestinal tract it binds to potassium in exchange for calcium primarily in the colon the potassium is then excreted from the body through the normal excretion process important safety information contraindicationsveltassa is contraindicated in patients with a history of a hypersensitivity reaction to veltassa or any of its components worsening of gastrointestinal motility  use of veltassa should be avoided in patients with severe constipation bowel obstruction or impaction including abnormal postoperative bowel motility disorders because veltassa may be ineffective and may worsen gastrointestinal conditions patients with a history of bowel obstruction or major gastrointestinal surgery severe gastrointestinal disorders or swallowing disorders were not included in clinical studies hypomagnesemiaveltassa binds to magnesium in the colon which can lead to hypomagnesemia in clinical studies hypomagnesemia was reported as an adverse reaction in  percent of patients treated with veltassa approximately  percent of patients in clinical trials developed hypomagnesemia with a serum magnesium value  mgdl doctors should monitor serum magnesium and consider magnesium supplementation in patients who develop low serum magnesium levels adverse reactionsthe most common adverse reactions incidence ≥ percent are constipation hypomagnesemia diarrhea nausea abdominal discomfort and flatulence mild to moderate hypersensitivity reactions were reported in  percent of patients treated with veltassa and included edema of the lips for veltassa’s full us prescribing information please visit httpswwwveltassacompipdf about relypsa increlypsa inc a vifor pharma group company is a biopharmaceutical company focused on the discovery development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract thecompanys first medicine veltassa® patiromer for oral suspension was developed based on relypsas rich legacy in polymer science more information is available at wwwrelypsacom about vifor pharma groupvifor pharma group formerly galenica group is a global specialty pharmaceuticals company it aims to become the global leader in iron deficiency nephrology and cardiorenal therapies the company is the partner of choice for specialty pharmaceuticals and innovative patientfocused solutions vifor pharma group strives to help patients around the world with severe and chronic diseases lead better healthier lives the company develops manufactures and markets pharmaceutical products for precision patient care vifor pharma group holds a leading position in all its core business activities and consists of the following companies vifor pharma vifor fresenius medical care renal pharma a joint company with fresenius medical care relypsa and om pharma vifor pharma group is headquartered in switzerland and listed on the swiss stock exchange six swiss exchange vifn isin ch for more information please visit wwwviforpharmacom contact tara cooper     mediarelypsacom related articles other press releases by relypsa inc relypsa presents veltassa® phase  data showing consistent efficacy and safety whether taken with or without food in patients with hyperkalemia april    relypsa announces publication of results of veltassa drugdrug interaction studies in journal of cardiovascular pharmacology and therapeutics february    fda approves supplemental new drug application for veltassa removing boxed warning regarding drugdrug interactions november    relypsa announces data on the treatment and impact of hyperkalemia to be presented at asn kidney week  november    relypsa announces phase  study shows veltassa® demonstrated similar efficacy and safety whether given with or without food in patients with hyperkalemia august     other news releases in product  services announcement in the last  days  other news releases in health in the last  days profile relypsa inc   subscribe via rss  subscribe via atom  javascript redwood city california united states contact data contact tara cooper     mediarelypsacom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files relypsa inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved pharmaceutical  medicinal products in redwood city ca  san mateo county redwood city ca pharmaceutical  medicinal products  selected  recently viewed sign up sign in add business find businesses deals content videos  businesses deals content videos near    search home food  fun shopping  savings local services health travel bb filters   has website  products   injectable m  services   deliveries  year started         years in business     categories pharmaceutical products manufacturepharmaceutical preparationspharmaceutical preparation manufacturingpharmaceutical  medicinal productsdrugs  drug proprietaries  toiletries more  pharmaceutical products wholesale  manufacturerspharmaceutical productsdrugs proprietaries  sundriesdrugs proprietaries  sundries pharmaceutical  medicinal products in redwood city ca  san mateo county displaying all  businesses type businesses content deals videos filtered clear relypsa inc pharmaceutical  medicinal products in redwood city ca locations    cardinal way redwood city ca     saginaw dr redwood city ca select save send a p pharma inc pharmaceutical companies in redwood city ca  saginaw dr redwood city ca    select save send oncomed pharmaceutical inc drugs  drug proprietaries  toiletries in redwood city ca  chesapeake dr redwood city ca    select save send biostride inc drugs  drug proprietaries  toiletries in redwood city ca  douglas ave redwood city ca    select save send copyright   hubbiz®  contact  terms of use  privacy policy  request api access  facebook  twitter  some data from acxiom  i didnt find what i want  the search is too slow  the search is difficult to use  i want to contact hubbiz relypsa inc  ipo candy skip to primary navigation skip to content becomeamember ipo candyeveryones favorite site for ipo insights and analysismain navigationhome » relypsa increlypsa inc  by relypsa inc a biopharmaceutical company focuses on the development and commercialization of nonabsorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases in the united states its lead product candidate includes patiromer a nonabsorbed potassium binding polymer that completed phase iii clinical trial for the treatment of hyperkalemia the company was founded in  and is based in redwood city california relypsa inc relypsa inc a biopharmaceutical company focuses on the development and commercialization of nonabsorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases in the united states its lead product candidate includes patiromer a nonabsorbed potassium binding polymer that completed phase iii clinical trial for the treatment of hyperkalemia the company was founded in  and is based in redwood city california twitter facebook google linkedin relypsa incprelypsa inc a biopharmaceutical company focuses on the development and commercialization of nonabsorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases in the united states its lead product candidate includes patiromer a nonabsorbed potassium binding polymer that completed phase iii clinical trial for the treatment of hyperkalemia the company was founded in  and is based in redwood city californiap caunited statesphone  rlyp drugs not absorbed for treatments documents roadshow main categoryhealthcare categoriesdrugs contact httpwwwrelypsacom  address cardinal way redwood city california  united states we love ipos the ipo market provides a magical window into the most exciting technologies emerging consumer trends and important business developments  all testing their mettle in the crucible of the public markets we are constantly learning and researching to deliver the best insights available we are independent we have no vested interests driving our work all the investment banks and brokers on a deal are paid to do a sales and marketing job our job is to remain objective and use a factbased approach to evaluate the potential for an ipo we get the best ratings ipo candy has been recognized since  as the single best place to get commentary analysis and assets in the ipo market the most common writein comment we get from users is that they love what we do we share everything we know with three decades of research under our belt we want to share what we have learned and the best practices we have discovered our ipo university contains texts videos and resources to share our process and help everyone develop their skills become an ipocandy member enjoy the benefits of full access to our content including access to ipo roadshow slideshows and transcripts included in our posts members also get additional insights via email receive our monthly candygram and have access to our ipo calendar become a member relypsa inc  revenue and financial reports  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  revenue  financial data company profile information for sales preparation marketing contacts competition revenue  financial available products company report pharmaceutical manufacturing industry report competitive reports relypsa inc revenue and financial data relypsa knows that too much of a good thing can be bad for your health a pharmaceutical company relypsa has developed a drug to treat hyperkalemia a potentially lifethreatening condition defined by high levels of potassium in the blood caused by kidney dysfunction the companys first commercialized medicine veltassa patiromer is an orally administered nonabsorbed drug that binds to ingested potassium and reduces its absorption by the body relypsa received fda approval for veltassa in  the company went public in  swiss firm galenica acquired relypsa for  billion in mid financials information for relypsa inc track this company’s financial condition view company report request your free trial income statement cash flowbalance sheetcredit rating income statement mil  revenue  gross profit  operating income  net income  diluted eps  cash flow mil  cash at the beginning of the year  net operating cash  net investing cash  net financing cash  net change in cash  cash at end of the year  capital expenditure  assets mil  current assets cash  net receivables  inventories  other income assets  asset summary total current assets  net fixed assets  other noncurrent assets  total assets  liabilities mil  current liabilities accounts payable  short term debt  other current liabilities  liability summary total current liabilities  long term debt  other noncurrent liabilities  total liabilities  stakeholders equity mil  equity preferred stock equity  common stock equity  equity summary total equity  shares outstanding  credit rating low these businesses have a low projected risk of delinquency and a moderate to low risk of failure need to go deeper no problem save time with complex financial data at your fingertips access financial statements sec filings earnings estimates and more call   to talk to a business information consultant request your free trial   free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days